Your next hire is a PhD immunologist or a regulatory affairs director choosing between your Series B and a stable seat at a company with 10x your headcount. Winston Francois builds the employer brand that makes the smaller, riskier offer the smarter career move.
The Problem
You are recruiting against Big Pharma's checkbook with a startup's cash position
A candidate weighing your offer against Merck or Genentech is not comparing job descriptions, they are comparing risk-adjusted total comp against career stability. Most biotech and pharma companies respond by trying to match compensation line items instead of reframing the decision around equity upside, scientific ownership, and speed to impact. Without a deliberate positioning strategy, every offer conversation defaults to a comp negotiation you cannot win on price alone.
The talent pool for your open roles is measured in hundreds of people, not thousands
A regulatory affairs specialist with FDA submission experience in your specific modality, or a bench scientist with the right assay background, is not a role you fill from a generic job board. These candidates are known quantities inside a small, tightly networked community, and they hear about your company's reputation through conference hallways and LinkedIn before they ever see a job posting. If your employer brand is invisible or generic in that circle, you are not in the consideration set at all.
Your board is watching hiring velocity as a proxy for clinical execution risk
When a key regulatory or clinical operations hire slips, it does not stay an HR problem. Investors read a stalled search as a signal that the company cannot execute against its milestone timeline, and that perception shows up in board meetings and follow-on conversations. Employer branding in this vertical is not a nice-to-have marketing layer, it is part of how you protect your credibility with the people who control your next round.
Every word in your recruiting materials has to survive legal and regulatory review
You cannot write the kind of bold, outcome-driven recruiting copy a SaaS company can, because overstating what your drug does or implying clinical results that have not been established creates real regulatory and reputational exposure. Add in the reality that a single trial setback or FDA letter can become public news within hours, and most biotech employer brands end up either overly cautious and forgettable, or they get burned trying to sound compelling and end up compliance flagged.
How We Help
We start with an assessment, not a brand workshop.
From there we build the positioning: what you can credibly claim about scientific ownership, speed of decision-making, equity structure, and the specific milestone the candidate would be joining to help hit. We write this in close coordination with your regulatory and legal function, because employer branding claims in this space live under the same scrutiny as any external communication.
Execution covers the full candidate-facing surface: career site content, role-specific job description rewrites for your hardest-to-fill scientific and regulatory positions, a LinkedIn and employee-advocacy cadence built around your actual scientists and clinical team rather than stock photography, and recruiter-facing collateral your talent team can use in outreach to passive candidates who are not actively job searching.
We also build the internal side: how your hiring managers talk about the role in a first call, what your offer stage messaging says about equity and mission alignment, and what your onboarding communication reinforces in the first 90 days so new hires do not regret the decision within a quarter.
Measurement is built around what your leadership actually cares about: time-to-fill on your hardest scientific and regulatory roles, offer acceptance rate against competing offers, quality and volume of inbound applications for roles you used to have to source aggressively, and retention through the first year for hires made under the new positioning.
What makes this different from a branding agency engagement is the model itself. You get a fractional team that has run growth and talent functions inside operating companies, not a creative shop delivering a brand book and disappearing.
What we deliver
- Employer brand positioning document reviewed and cleared with your regulatory/legal function
- Career site messaging and page-level copy rewrite
- Role-specific job description overhauls for priority scientific, clinical, and regulatory openings
- LinkedIn and employee-advocacy content cadence built around your own scientists and staff
- Passive-candidate outreach and recruiter talk-track materials
- Hiring manager and offer-stage messaging guide
- Quarterly reporting against time-to-fill, offer acceptance, and first-year retention
A candidate choosing between your Series B and Big Pharma is not comparing salaries, they are comparing risk-adjusted stories about their own career, and most biotech companies never bother to tell one.
Our Methodology
We run this as a 90-day sprint, not an open-ended retainer with no defined endpoint. Days 1 through 30 are assessment and positioning: audit of current recruiting materials and candidate data, structured conversations with your hiring managers and a sample of recent hires, and a cleared positioning framework that your regulatory function has signed off on before we write a single public-facing sentence. Days 31 through 60 are build and launch: career site and job description rewrites go live, the employee-advocacy and LinkedIn cadence starts, and recruiter-facing materials get into your talent team's hands for the searches already in flight. Days 61 through 90 are measurement and iteration, where we look at real offer and interview data against the new positioning and adjust messaging for the roles that are still not converting.
What is different from a traditional agency retainer is that we are embedded, not delivering from a distance. We join your hiring manager syncs when a key search is stalling, we sit in on debriefs when a strong candidate declines, and we treat a slipped regulatory affairs hire as a live problem to solve that week, not an item for next quarter's brand review. The output is not a static brand book that sits in a shared drive, it is a working recruiting motion your team can run without us once the sprint closes.
How We Work
The first 30 days are lightweight on your team's time: we need access to your ATS data, current job postings, career site, and 3 to 5 conversations with people involved in recent hiring decisions. Our team does the audit and positioning work, and you review and approve the framework before it touches anything public.
From day 30 onward, expect a standing weekly check-in with whoever owns talent acquisition or people operations on your side, plus async Slack access for anything that cannot wait a week, like a candidate decline you want us to help debrief or an offer letter that needs positioning language fast. We are not a vendor you email into a queue.
Team structure is fractional by design: you get senior operators who have built employer brand and recruiting functions before, not a junior account team executing a brief. For a Series A or B biotech, that usually means one lead strategist and one content/execution partner, scaled up if you are running parallel searches across R&D, regulatory, and commercial simultaneously.
By day 90 you should have a positioning framework your team owns, a live career site and job posting set built on it, and real data on whether it is moving offer acceptance and time-to-fill on your hardest roles. If your biotech or pharma company needs employer branding that survives legal review and actually wins offers against Big Pharma comp, we should talk.
- Faster time-to-fill on scarce scientific and regulatory roles
- Higher offer acceptance rate against competing Big Pharma offers
- Stronger inbound candidate pipeline for roles that used to require aggressive sourcing
- Improved first-year retention on hires made under the new positioning
- Recruiting materials that clear regulatory and legal review without repeated rewrites
- A recruiting motion your internal team can run independently after the sprint
If your biotech & pharma company needs employer branding leadership, we should talk.
Expand your marketing team output with our experts
Let us take a custom approach to your growth goals by assembling and leading the best-in-class marketing team to support your next stage.
Frequently asked questions
How much does employer branding for a biotech or pharma company cost?
Pricing depends on how many role categories we are building positioning and content for, and whether you need parallel tracks for R&D, regulatory, and commercial hiring. A typical Series A or B engagement structured as a 90-day sprint runs in the $15K-$35K range.
How long until we see a difference in candidate response?
Job description and career site changes go live around day 45, and you typically see a shift in inbound application quality within the first few weeks after that. Offer acceptance rate takes longer to move because it depends on your existing pipeline cycling through, so we treat the 90-day mark as the first real data point, with clearer trends by month four or five.
How does your team work with our existing recruiters and hiring managers?
We do not replace your talent acquisition function, we give it better material to work with. Recruiters get talk tracks and outreach messaging for passive candidates, hiring managers get a positioning guide for how to open a first call, and we join live searches that are stalling to help debrief declined offers in real time rather than after the fact.
How is this different from hiring a branding agency or a recruiting firm?
A branding agency typically delivers a brand book and does not touch your actual job postings, career site copy, or offer-stage messaging. A recruiting firm sources candidates but does not fix why qualified candidates are declining your offers.
How do you measure ROI on employer branding?
We track time-to-fill on your priority scientific and regulatory roles, offer acceptance rate against competing offers, volume and quality of inbound applications compared to your pre-engagement baseline, and first-year retention for hires made after the new positioning launched. We report against these numbers on a set cadence rather than reporting soft engagement metrics that do not connect to hiring outcomes.
Can you write recruiting content that references our drug's clinical results?
We can reference what is publicly disclosed and cleared through your regulatory and legal function, but we will not write recruiting copy that implies efficacy or trial outcomes beyond what has been established and approved for external communication. Every piece of positioning and content goes through your compliance review before publication, and we build the messaging to be compelling within those constraints rather than around them.
Is our company a good fit for this, or are we too early stage?
This works best for Series A through growth-stage biotech and pharma companies with $5M to $100M in ARR or equivalent funding, who have real, repeated hiring pain on scientific, clinical, or regulatory roles and a board or investor group paying attention to hiring velocity. If you are pre-Series A with one or two open roles, a fractional 90-day sprint is likely more structure than you need yet.
